187 related articles for article (PubMed ID: 38751615)
1. Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives.
Pinto M; Silva TB; Sardão VA; Simões R; Albuquerque B; Oliveira PJ; Valente MJ; Remião F; Soares-da-Silva P; Fernandes C; Borges F
ACS Pharmacol Transl Sci; 2024 May; 7(5):1637-1649. PubMed ID: 38751615
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
Kaakkola S
Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
[TBL] [Abstract][Full Text] [Related]
3. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
[TBL] [Abstract][Full Text] [Related]
4. Tau-derived-hexapeptide 306VQIVYK311 aggregation inhibitors: nitrocatechol moiety as a pharmacophore in drug design.
Mohamed T; Hoang T; Jelokhani-Niaraki M; Rao PP
ACS Chem Neurosci; 2013 Dec; 4(12):1559-70. PubMed ID: 24007550
[TBL] [Abstract][Full Text] [Related]
5. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
6. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
8. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
Grünig D; Felser A; Bouitbir J; Krähenbühl S
Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
[TBL] [Abstract][Full Text] [Related]
9. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Kaakkola S; Gordin A; Männistö PT
Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
[TBL] [Abstract][Full Text] [Related]
10. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
[TBL] [Abstract][Full Text] [Related]
11. Tissue and interspecies comparison of catechol-
Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
[TBL] [Abstract][Full Text] [Related]
12. Toxicology and safety of COMT inhibitors.
Haasio K
Int Rev Neurobiol; 2010; 95():163-89. PubMed ID: 21095462
[TBL] [Abstract][Full Text] [Related]
13. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Forester SC; Lambert JD
Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
[TBL] [Abstract][Full Text] [Related]
15. Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.
Silva T; Mohamed T; Shakeri A; Rao PP; Martínez-González L; Pérez DI; Martínez A; Valente MJ; Garrido J; Uriarte E; Serrão P; Soares-da-Silva P; Remião F; Borges F
J Med Chem; 2016 Aug; 59(16):7584-97. PubMed ID: 27463695
[TBL] [Abstract][Full Text] [Related]
16. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
Robinson RG; Smith SM; Wolkenberg SE; Kandebo M; Yao L; Gibson CR; Harrison ST; Polsky-Fisher S; Barrow JC; Manley PJ; Mulhearn JJ; Nanda KK; Schubert JW; Trotter BW; Zhao Z; Sanders JM; Smith RF; McLoughlin D; Sharma S; Hall DL; Walker TL; Kershner JL; Bhandari N; Hutson PH; Sachs NA
ACS Chem Neurosci; 2012 Feb; 3(2):129-40. PubMed ID: 22860182
[TBL] [Abstract][Full Text] [Related]
17. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
[TBL] [Abstract][Full Text] [Related]
18. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Borges N
Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
[TBL] [Abstract][Full Text] [Related]
19. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
20. Structural and Computational Analyses of the Unique Interactions of Opicapone in the Binding Pocket of Catechol
Takebe K; Suzuki M; Kuwada-Kusunose T; Shirai S; Fukuzawa K; Takamiya T; Uzawa N; Iijima H
J Chem Inf Model; 2023 Jul; 63(14):4468-4476. PubMed ID: 37436881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
